Fennec Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
6analysts covering
FY Revenue (est.)
$69.8Mnext fiscal year
FY EPS (est.)
$0.30next fiscal year
Monitoring Framework
Key Performance Indicators
Net Product Sales (PEDMARK) Quarterly15.1M
Cash and Cash Equivalents Quarterly40.2MTarget: Sufficient to fund current operating plan
Watch Items
- Market penetration in the Adolescent and Young Adult (AYA) populationTrigger: Slower than expected adoption or low vial utilization per accountAction: Re-evaluate commercial field force strategy and expand home infusion services under the Fennec HEARS program.
- NCCN Guidelines classification upgradeTrigger: Failure to upgrade PEDMARK clinical evidence from Category 2A to Category 1Action: Monitor ongoing investigator-sponsored trials (ISTs) and support publication of real-world clinical data.
Research as of 20 Jun 2026